Structure Therapeutics (NASDAQ:GPCR) Earns “Overweight” Rating from Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $65.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 66.62% from the stock’s previous close.

Several other research firms have also weighed in on GPCR. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price target on the stock. BMO Capital Markets upped their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. Finally, JMP Securities decreased their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $84.63.

Structure Therapeutics Trading Down 4.5 %

Shares of Structure Therapeutics stock traded down $1.83 during trading on Monday, reaching $39.01. The stock had a trading volume of 219,178 shares, compared to its average volume of 787,873. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -50.66 and a beta of -3.52. The stock has a fifty day moving average price of $38.12 and a two-hundred day moving average price of $39.67. Structure Therapeutics has a 52 week low of $26.61 and a 52 week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts forecast that Structure Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock valued at $178,216,000 after buying an additional 3,504,747 shares in the last quarter. Driehaus Capital Management LLC raised its stake in Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after purchasing an additional 150,000 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after purchasing an additional 1,333,333 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 34.5% during the first quarter. Janus Henderson Group PLC now owns 2,076,700 shares of the company’s stock worth $88,994,000 after purchasing an additional 532,284 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.